Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer

Introduction: The International Association for the Study of Lung Cancer recently proposed new M descriptors for the next edition of the TNM classification for NSCLC, subdividing the current M1b category into two subcategories: M1b, which indicates a solitary extrathoracic metastasis in a single organ, and M1c, which indicates multiple extrathoracic metastasis. The purpose of this study was to validate the prognostic value of the newly proposed M descriptors in an independent cohort with multivariate and subgroup analysis. Methods: A total of 1024 patients in a consecutive lung cancer database who had stage IV NSCLC treated between 2011 and 2014 were analyzed. Newly proposed M staging was used for classification and comparison of survival. Adjustment for other clinical covariates and subgroup analysis was conducted. Results: According to the newly proposed M descriptors, 262 patients (25.6%), 152 patients (14.8%), and 610 patients (59.6%) were classified into the subgroups M1a, M1b, and M1c, respectively. The median overall survival times were 22.5, 17.8, and 13.6 months for the M1a, M1b, and M1c groups, respectively (p < 0.001). After adjustment for other covariates, Cox proportional hazards regression revealed statistically significantly shorter overall survival for the M1b group than for the M1a group (hazard ratio = 1.30; 95% confidence interval: 1.03–1.65, p = 0.03) and for the M1c than the M1b group (hazard ratio = 1.57; 95% confidence interval: 1.28–1.93, p < 0.001). These differences showed a consistent tendency regardless of pathologic and molecular subtypes. Conclusions: The newly proposed M descriptors have prognostic value in patients with stage IV NSCLC.

[1]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[2]  B. Yaremko,et al.  Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. , 2013, Lung cancer.

[3]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Gwan Ho Lee,et al.  Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. , 2012, Lung cancer.

[5]  R. Crisci,et al.  Surgical approach in the oligometastatic patient. , 2018, Annals of translational medicine.

[6]  Robert D Timmerman,et al.  Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. , 2006, Seminars in radiation oncology.

[7]  J. Vansteenkiste,et al.  Survival after resection of synchronous bilateral lung cancer. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  Hisao Asamura,et al.  The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  R. Cameron,et al.  Video-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative , 2008, Surgical Endoscopy.

[10]  Jin-Hyoung Kang,et al.  Stereotactic radiosurgery for brain metastasis in non-small cell lung cancer , 2015, Radiation oncology journal.

[11]  Dong-Wan Kim,et al.  Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer , 2013, International Journal of Clinical Oncology.

[12]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[13]  C. Lee,et al.  Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. , 2012, Lung cancer.

[14]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[15]  H. Dienemann,et al.  Surgical treatment of oligometastatic non-small cell lung cancer. , 2010, Lung cancer.

[16]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[17]  R W Makuch,et al.  Adjusted survival curve estimation using covariates. , 1982, Journal of chronic diseases.

[18]  Tian-cheng Zhao,et al.  Effect of synchronous solitary bone metastasectomy and lung cancer resection on non-small cell lung cancer patients. , 2016, Oncology letters.

[19]  H. Uno,et al.  Comparative effectiveness of stereotactic radiosurgery versus whole‐brain radiation therapy for patients with brain metastases from breast or non–small cell lung cancer , 2016, Cancer.

[20]  P. Garg,et al.  Role of positron emission tomography-computed tomography in non-small cell lung cancer. , 2016, World journal of methodology.

[21]  J. Kollmeier,et al.  Metastasectomy for synchronous solitary non-small cell lung cancer metastases. , 2014, The Annals of thoracic surgery.

[22]  M. Burt,et al.  Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. , 1992, The Journal of thoracic and cardiovascular surgery.

[23]  M. Guerrieri,et al.  Laparoscopic Anterior Adrenalectomy for the Treatment of Adrenal Metastases , 2003, Surgical laparoscopy, endoscopy & percutaneous techniques.

[24]  Laura W. Christianson,et al.  Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. , 2014, Lung cancer.

[25]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.